IMPDH2 and cancer: Our laboratory previously published an autoantibody panel which consisted of Annexin 1, Annexin 2, IMPDH2, HSP70, PGAM1, and Ubiquillin 1, and properly classified 93% within five clinically distinct groups: osteoarthritis, “cancer-free” control, asthma/COPD, benign nodule, and NSCLC [16].